Monod Bio, a Seattle-based AI-enabled protein design company, and SignalChem Biotech Inc., a wholly-owned subsidiary of Sino Biological, Inc., have announced a non-exclusive licensing agreement covering Monod Bio's proprietary LuxSit luciferase technology and NovoBodies. The agreement allows SignalChem Biotech to incorporate these AI-designed proteins into its custom luminescent assay development and protein-fusion services for third-party researchers.
The partnership underscores a growing trend in the life sciences industry: the integration of artificial intelligence into the design of biological tools. Monod Bio's LuxSit is an AI-designed luciferase engineered for robust luminescent biosensors, while NovoBodies are compact, highly stable binding proteins designed for high-performance recognition of various targets. Together, these technologies provide versatile tools for developing customized assays and discovery workflows.
Dr. Rob Burgess, Chief Business Officer of Sino Biological, highlighted the practical benefits: "By incorporating Monod Bio's AI-designed protein technologies into SignalChem's custom assay platform, we can help researchers obtain high quality discovery candidates more rapidly. This agreement and the corresponding licensed technology strengthen our ability to help customers address complex biological questions and advance their research programs more efficiently."
The collaboration expands SignalChem’s specialized contract research organization (CRO) capabilities and supports Sino Biological’s broader strategy of incorporating AI-enabled technologies across its global life science tools and services portfolio. For Monod Bio, this partnership represents a key validation of its "Monod Inside" model, which aims to integrate AI-designed proteins into commercial products and services.
Daniel Silva Manzano, PhD, Chief Executive Officer of Monod Bio, stated, "SignalChem Biotech and Sino Biological have the scientific expertise, customer reach and service infrastructure to bring these technologies to a broad customer base. This partnership expands the reach of our platform and reinforces the value of our Monod Inside model for integrating AI-designed proteins into commercial products and services."
For researchers, the availability of these AI-designed tools in custom assay services could accelerate the development of sensitive and specific assays, potentially speeding up drug discovery and other life science research. The use of AI in protein design is expected to reduce the time and cost associated with traditional protein engineering, making advanced tools more accessible.
The announcement comes at a time when AI is increasingly being applied to biological challenges, from drug discovery to diagnostics. By licensing these technologies, Sino Biological and SignalChem Biotech are positioning themselves at the forefront of this innovation, offering customers access to state-of-the-art tools that may improve research outcomes.
Sino Biological is an international life science tools provider with facilities across Asia, North America and Europe. SignalChem Biotech provides specialized reagents and CRO services supporting drug discovery and life science research. Monod Bio uses AI-powered de novo protein design to create novel binders, biosensors, and other functional proteins. Through its Monod Inside model, Monod Bio partners with life science companies to integrate its technologies into next-generation products and services.
While the financial impact on Sino Biological is not expected to be material in the near term, the strategic value of incorporating AI-designed proteins into its service offerings could enhance its competitive position in the CRO market. As the life sciences industry continues to embrace AI, collaborations like this one may become increasingly common, shaping the future of research tools and services.
